Pure Global
NCT05923268

Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy

SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Technetium-99m-labelled Designed Ankyrin Repeat Proteins ([99mTc]Tc-G3-(G3S)3C)
Tomsk National Research Medical Center of the Russian Academy of Sciences·ClinicalTrials.gov·drugEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Breast Cancer Female
Drug/Device/Intervention
[99mTc]Tc-G3-(G3S)3C
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Location
Tomsk, Russian Federation
Timeline & enrollment
Phase
N/A
Start date
Jun 04, 2023
End date
Jun 15, 2024
Enrollment
10 participants
Primary outcome

Gamma camera-based whole-body [99mTc]Tc-G3-(G3S)3C uptake value (%),SPECT-based [99mTc]Tc-G3-(G3S)3C uptake value in tumor lesions (counts) [99mTc]Tc-G3-(G3S)3C uptake coinciding with tumor lesions will be assessed using single-photon emission computed tomography and measured in counts,SPECT-based [99mTc]Tc-G3-(G3S)3C background uptake value (counts),Tumor-to-background ratio (SPECT)

Summary

The study should evaluate distribution of [99mTc]Tc-G3-(G3S)3C in patients with primary
 HER2-positive and HER2-negative breast cancer

ICD-10 classifications
Malignant neoplasm: Breast, unspecifiedMalignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedPersonal history of malignant neoplasm of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05923268
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05923268 through Pure Global AI's free database. This phase not specified trial is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences and is currently Enrolling by invitation. The study focuses on Breast Cancer Female. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.